You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Idelalisib for treating refractory follicular lymphoma

  • Technology appraisal guidance
  • Reference number: TA604
  • Published:  02 October 2019
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Draft guidance
  4. Invitation to participate

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 155 KB)

    Published:
    02 October 2019

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 383 KB)

    Published:
    23 August 2019
  • Committee papers (Unknown 2.31 MB)

    Published:
    23 August 2019

Draft guidance

  • Draft guidance

  • Appraisal consultation document (online commenting)

  • Appraisal consultation document (PDF version) (PDF 406 KB)

    Published:
    03 October 2018
  • Committee papers (PDF 7.98 MB)

    Published:
    03 October 2018
  • Public committee slides (PDF 958 KB)

    Published:
    03 October 2018

Invitation to participate

  • Final scope (PDF 218 KB)

    Published:
    05 April 2018
  • Draft scope and provisional matrix comments table (post-referral) (PDF 355 KB)

    Published:
    05 April 2018
  • Equality impact assessment (Scoping) (PDF 173 KB)

    Published:
    05 April 2018
  • Final matrix (MSWord 61 KB)

    Published:
    09 August 2018